Finasteride (MK‐906) in the treatment of benign prostatic hyperplasia
Author:
- The Finasteride Study GroupTGThe Finasteride Study Group
- 1 January 1993
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 22 (4) , 291-299
Abstract
The effects of finasteride, a potent 5α‐reductase inhibitor, were assessed in 750 patients with benign prostatic hyperplasia (BPH) in a multicenter, double‐blind, placebo‐controlled study. Patients were randomized to finasteride, 1 or 5 mg, or placebo, daily for 12 months. The following changes were seen with finasteride 5 mg after 12 months: (1) Serum dihydrotestosterone decreased by 62% compared to no change with placebo (P < 0.001); (2) serum prostate‐specific antigen (PSA) decreased by 46% compared to no change with placebo (P < 0.001); (3) prostate volume was reduced by 22% compared to a 5% decrease with placebo (P < 0.001); (4) maximum urinary flow rate increased by 1.7 ml/sec compared to a 0.4 ml/sec increase with placebo (P < 0.025); (5) total urinary symptom scores decreased by 3.3 points compared to a 2.0 point decrease with placebo (P = 0.005), and (6) obstructive symptom scores decreased by 2.1 points compared to a 1.4 point decrease with placebo (P = 0.017). The effects of finasteride 1 mg were similar to 5 mg, except in urinary symptoms, where no significant differences between 1 mg and placebo were seen. Patients treated with 5 mg finasteride demonstrated significantly greater improvements in urological status (assessed by the investigator) and the troublesome symptom score, compared to placebo. Treatment with finasteride was well tolerated. We conclude that finasteride is an effective medical therapy for a significant proportion of patients with BPH.Keywords
This publication has 14 references indexed in Scilit:
- Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*The Journal of Clinical Endocrinology & Metabolism, 1990
- Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasiaThe Prostate, 1990
- Mortality and Reoperation after Open and Transurethral Resection of the Prostate for Benign Prostatic HyperplasiaNew England Journal of Medicine, 1989
- Treatment of Benign Prostatic Hyperplasia by Androgen Deprivation: Effects on Prostate Size and Urodynamic ParametersJournal of Urology, 1989
- The Effect of Nafarelin Acetate, a Luteinizing-Hormone–Releasing Hormone Agonist, on Benign Prostatic HyperplasiaNew England Journal of Medicine, 1987
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984
- 4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor.Journal of Biological Chemistry, 1984
- Male Peak Urinary Flow Rate: Relationships to Volume Voided and AgeJournal of Urology, 1979
- Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male PseudohermaphroditismScience, 1974
- Familial Incomplete Male Pseudohermaphroditism, Type 2New England Journal of Medicine, 1974